Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Submission of BRSR for the FY 2024-25'.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has filed its annual Business Responsibility and Sustainability Report (BRSR) for FY 2024-25, which is a SEBI-mandated ESG disclosure. The company reported standalone turnover of ₹6,032.63 crore and net worth of ₹5,197.79 crore, with 57% of revenue coming from exports across 76 countries. It employs 15,682 permanent employees and operates 9 manufacturing plants and 2 R&D centres in India. Key ESG progress includes commissioning a second 12 MW solar park (bringing renewable energy share to 39%), achieving 10% reduction in Scope 1+2 emissions versus FY21 baseline, and planting 25,000+ trees toward its 50,000 tree goal by 2027. The company also developed 102 recharge wells covering 85% of its water consumption. Its SBTi-approved targets include 63% absolute GHG reduction by FY2034 and 90% by FY2050. The report was assured by Bureau Veritas India on a limited assurance basis.
This is a routine regulatory compliance filing and is unlikely to cause any short-term stock price movement. However, it demonstrates the company's progress on ESG commitments and confirms it has SBTi-validated emissions targets, which may appeal to ESG-focused investors.